Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Free Cash Flow data on file, last reported at -$89.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 12.13% year-over-year to -$89.3 million in Q1 2026; TTM through Mar 2026 was -$249.7 million, a 4.06% decrease from a year earlier, with the FY2025 full-year figure at -$240.1 million, down 15.78% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$89.3 million, down from -$72.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for KYMR reached as high as $9.0 million in Q4 2023 and fell as low as -$89.3 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$46.6 million across 5 years, with a median of -$47.0 million in 2024.
• Across the five-year window, Free Cash Flow jumped 123.52% in 2023 and slumped 800.47% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$38.1 million in 2022, then soared by 123.52% to $9.0 million in 2023, then slumped by 800.47% to -$62.7 million in 2024, then retreated by 15.7% to -$72.6 million in 2025, then decreased by 23.02% to -$89.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$89.3 million in Q1 2026, -$72.6 million in Q4 2025, and -$27.3 million in Q3 2025.